Ambroxol (Relent Plus Syrup) is a mucolytic agent, prescribed for various respiratory diseases such as emphysema with bronchitis pneumoconiosis, chronic inflammatory pulmonary conditions, ...

Researchers at Lawson Research Institute are studying Ambroxol - a common cough medicine in Europe - as a potential treatment for dementia linked to Parkinson’s disease LONDON, Ont. – Dementia poses a ...

The Phase III trial will enroll over 300 people with Parkinson's disease, some of whom will receive the cough drug ambroxol. Reading time 3 minutes An important clinical trial for Parkinson’s disease ...

Ambroxol, a drug used in cough syrup to break up phlegm, may be worthy of further study as a neuroprotective compound in Parkinson's disease, AiM-PD trial results suggested. In a small, open-label, ...

A landmark Phase 3 clinical trial is beginning in the UK, testing whether a common cough medicine can be used to treat Parkinson's disease. Early studies indicate the 50-year-old drug can cross into ...

A recent phase 2 clinical trial reveals that Ambroxol, a common cough medicine, shows promise in stabilizing psychiatric symptoms and potentially slowing cognitive decline in Parkinson's disease ...

Please provide your email address to receive an email when new articles are posted on . Although a high number of adverse events were logged, most were mild to moderate in severity. The effects of ...

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol - a cough medicine used safely for decades in Europe - can ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

A 12-month study conducted by researchers at Lawson Research Institute found that Ambroxol helped stabilise psychiatric symptoms, improved cognitive function, and protected against brain damage in ...